<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 13 Mar 2025 08:15:58 +0000</lastbuilddate>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: The Impact of Patiromer on Heart Failure Treatment With Angiotensin Inhibitors and MRAs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074478/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):e115. doi: 10.1016/j.jacc.2024.12.029.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074478/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074478</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.029>10.1016/j.jacc.2024.12.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074478</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Jeffrey Budden</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: The Impact of Patiromer on Heart Failure Treatment With Angiotensin Inhibitors and MRAs</dc:title>
<dc:identifier>pmid:40074478</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.029</dc:identifier>
</item>
<item>
<title>The Impact of Patiromer on Heart Failure Treatment With Angiotensin Inhibitors and MRAs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074477/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):e113. doi: 10.1016/j.jacc.2024.09.1248.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074477/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074477</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1248>10.1016/j.jacc.2024.09.1248</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074477</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Wei-Zhen Tang</dc:creator>
<dc:creator>Qin-Yu Cai</dc:creator>
<dc:creator>Yun-Ren Pan</dc:creator>
<dc:creator>Tai-Hang Liu</dc:creator>
<dc:creator>Ying-Bo Li</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Impact of Patiromer on Heart Failure Treatment With Angiotensin Inhibitors and MRAs</dc:title>
<dc:identifier>pmid:40074477</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1248</dc:identifier>
</item>
<item>
<title>Reply: Urinary Metal Levels and Coronary Artery Calcification: Potential Confounders</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074476/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):e111. doi: 10.1016/j.jacc.2024.11.050.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074476/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074476</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.050>10.1016/j.jacc.2024.11.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074476</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Katlyn E McGraw</dc:creator>
<dc:creator>Steven Shea</dc:creator>
<dc:creator>Ana Navas-Acien</dc:creator>
<dc:creator>Tiffany R Sanchez</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Urinary Metal Levels and Coronary Artery Calcification: Potential Confounders</dc:title>
<dc:identifier>pmid:40074476</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.050</dc:identifier>
</item>
<item>
<title>Environmental Metal Exposure and Cardiovascular Disease Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074475/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):e109. doi: 10.1016/j.jacc.2024.10.127.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074475/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074475</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.127>10.1016/j.jacc.2024.10.127</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074475</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Jixuan Wu</dc:creator>
<dc:creator>Zili Zhang</dc:creator>
<dc:creator>Lei Zhang</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Environmental Metal Exposure and Cardiovascular Disease Risk</dc:title>
<dc:identifier>pmid:40074475</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.127</dc:identifier>
</item>
<item>
<title>Urinary Metal Levels and Coronary Artery Calcification: Potential Confounders</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074474/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):e107. doi: 10.1016/j.jacc.2024.09.1247.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074474/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074474</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1247>10.1016/j.jacc.2024.09.1247</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074474</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Richard A Chazal</dc:creator>
<dc:creator>Juan Lopez-Mattei</dc:creator>
<dc:creator>Juan Gaztañaga</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Urinary Metal Levels and Coronary Artery Calcification: Potential Confounders</dc:title>
<dc:identifier>pmid:40074474</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1247</dc:identifier>
</item>
<item>
<title>Clinical Effect of Genetic Testing in Inherited Cardiovascular Diseases: A 14-Year Retrospective Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Genetic testing in a clinical context identified a disease-causing variant in 24% of probands, thus highlighting the high yield of rare variant genetic testing. Beyond the impact on family screening, the genetic testing result affected clinical management. Access to allele frequency data from a local population refines variant interpretation and classification.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):988-999. doi: 10.1016/j.jacc.2024.11.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The clinical impact of genetic testing in a contemporary real-life cohort of patients with heritable cardiomyopathies or arrhythmias is not well defined. Additionally, the genetic spectrum of these conditions in the French-Canadian population is unknown, and interpretation of genetic variants can be challenging because of a known founder effect.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to evaluate the clinical utility of arrhythmia and cardiomyopathy genetic testing and assess the utility of allele frequency data from a local reference population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The study included consecutive probands seen at the Montreal Heart Institute Cardiovascular Genetics Centre (Montreal, Quebec, Canada) for suspected heritable cardiomyopathies or arrhythmias for which both clinical data and genetic testing results were available. The study analyzed the enrichment of recurrent rare genetic variants by comparing their prevalence in the case cohort with that of a local population cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 2,062 probands (mean age at diagnosis 47 ± 17 years) were included. Overall, genetic testing identified a pathogenic/likely pathogenic (P/LP) variant in 496 (24%) probands. A total of 9 variants had their classification changed after comparing their prevalence (case control enrichment) using a local population-based cohort. Genetic testing resulted in diagnostic refinement with a potential impact on clinical management in 168 (8%) probands.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Genetic testing in a clinical context identified a disease-causing variant in 24% of probands, thus highlighting the high yield of rare variant genetic testing. Beyond the impact on family screening, the genetic testing result affected clinical management. Access to allele frequency data from a local population refines variant interpretation and classification.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074473</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.025>10.1016/j.jacc.2024.11.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074473</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Steffany Grondin</dc:creator>
<dc:creator>Benjamin Neveu</dc:creator>
<dc:creator>Iness Soltani</dc:creator>
<dc:creator>Ahmed Amine Alaoui</dc:creator>
<dc:creator>Alexander Messina</dc:creator>
<dc:creator>Laurence Gaumond</dc:creator>
<dc:creator>Fabrice Demonière</dc:creator>
<dc:creator>Ken Sin Lo</dc:creator>
<dc:creator>Amélie Jeuken</dc:creator>
<dc:creator>Catherine Barahona-Dussault</dc:creator>
<dc:creator>Guillaume Sylvain-Drolet</dc:creator>
<dc:creator>Laura Robb</dc:creator>
<dc:creator>Johannie Gagnon</dc:creator>
<dc:creator>Evelyne Naas</dc:creator>
<dc:creator>Valérie-Anne Codina-Fauteux</dc:creator>
<dc:creator>Diana Margarita Victoria Moron</dc:creator>
<dc:creator>Sandra Therrien-Laperrière</dc:creator>
<dc:creator>Valérie Hay</dc:creator>
<dc:creator>Guillaume Lettre</dc:creator>
<dc:creator>Marie-A Chaix</dc:creator>
<dc:creator>Léna Rivard</dc:creator>
<dc:creator>Geneviève Giraldeau</dc:creator>
<dc:creator>Philippe L L'Allier</dc:creator>
<dc:creator>Patrick Garceau</dc:creator>
<dc:creator>Maxime Tremblay-Gravel</dc:creator>
<dc:creator>Julia Cadrin-Tourigny</dc:creator>
<dc:creator>Mario Talajic</dc:creator>
<dc:creator>Julie Amyot</dc:creator>
<dc:creator>Rafik Tadros</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Effect of Genetic Testing in Inherited Cardiovascular Diseases: A 14-Year Retrospective Study</dc:title>
<dc:identifier>pmid:40074473</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.025</dc:identifier>
</item>
<item>
<title>Do Potassium Binders Block Both the Benefits and the Risks of Mineralocorticoid Receptor Antagonists in Heart Failure?: The Four Anti-Aldosterone Myths</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074472/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):985-987. doi: 10.1016/j.jacc.2025.01.011.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074472/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074472</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.011>10.1016/j.jacc.2025.01.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074472</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Do Potassium Binders Block Both the Benefits and the Risks of Mineralocorticoid Receptor Antagonists in Heart Failure?: The Four Anti-Aldosterone Myths</dc:title>
<dc:identifier>pmid:40074472</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.011</dc:identifier>
</item>
<item>
<title>The Value of Case-Based Learning in Cardiovascular Medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074471/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1058. doi: 10.1016/j.jacc.2025.02.005.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074471/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074471</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.005>10.1016/j.jacc.2025.02.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074471</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Value of Case-Based Learning in Cardiovascular Medicine</dc:title>
<dc:identifier>pmid:40074471</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.005</dc:identifier>
</item>
<item>
<title>Best Practices for Imaging of Transcatheter Valve Failure: An Update From the Heart Valve Collaboratory</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>This updated Heart Valve Collaboratory framework addresses the growing concern for transcatheter valve failure (TVF) following transcatheter aortic valve replacement (TAVR). With the increasing volume of redo-TAV and surgical TAV explantation, there is a critical need for standardized pathways and protocols for evaluating TVF using echocardiography and cardiac computed tomography (CT) angiography. This document clarifies prior definitions of bioprosthetic valve deterioration and bioprosthetic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1042-1055. doi: 10.1016/j.jacc.2024.12.017.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This updated Heart Valve Collaboratory framework addresses the growing concern for transcatheter valve failure (TVF) following transcatheter aortic valve replacement (TAVR). With the increasing volume of redo-TAV and surgical TAV explantation, there is a critical need for standardized pathways and protocols for evaluating TVF using echocardiography and cardiac computed tomography (CT) angiography. This document clarifies prior definitions of bioprosthetic valve deterioration and bioprosthetic valve failure in a practical, imaging directed context for TAVR. It discusses various imaging modalities for diagnosing TVF, including echocardiography, cardiac CT angiography, cardiac magnetic resonance, and positron emission tomography/CT. Recommendations are provided on the systematic imaging for: 1) follow-up post-TAVR; 2) procedural planning for redo-TAV; and 3) post-redo-TAV, emphasizing the importance of regular monitoring and the need for comprehensive imaging data to optimize patient outcomes in the lifetime management of aortic valve disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074470</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.017>10.1016/j.jacc.2024.12.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074470</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Omar K Khalique</dc:creator>
<dc:creator>Syed Zaid</dc:creator>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Mohamed Abdel-Wahab</dc:creator>
<dc:creator>Miriama Akodad</dc:creator>
<dc:creator>Vinayak N Bapat</dc:creator>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>Daniel J Blackman</dc:creator>
<dc:creator>Philipp Blanke</dc:creator>
<dc:creator>Sabine Bleiziffer</dc:creator>
<dc:creator>Davide Capodanno</dc:creator>
<dc:creator>Joao L Cavalcante</dc:creator>
<dc:creator>Lakshmi P Dasi</dc:creator>
<dc:creator>Ole De Backer</dc:creator>
<dc:creator>Matthiew De Beuel</dc:creator>
<dc:creator>Alison Duncan</dc:creator>
<dc:creator>Marc R Dweck</dc:creator>
<dc:creator>Miho Fukui</dc:creator>
<dc:creator>Aakriti Gupta</dc:creator>
<dc:creator>Kentaro Hayashida</dc:creator>
<dc:creator>Howard C Herrmann</dc:creator>
<dc:creator>Tsuyoshi Kaneko</dc:creator>
<dc:creator>Nicole Karam</dc:creator>
<dc:creator>Jaffar M Khan</dc:creator>
<dc:creator>Jan Kovac</dc:creator>
<dc:creator>Uri Landes</dc:creator>
<dc:creator>Jonathon A Leipsic</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Mahesh V Madhavan</dc:creator>
<dc:creator>Moody M Makar</dc:creator>
<dc:creator>Raj R Makkar</dc:creator>
<dc:creator>Mouaz Al Mallah</dc:creator>
<dc:creator>David Meier</dc:creator>
<dc:creator>Thomas Modine</dc:creator>
<dc:creator>Atsushi Okada</dc:creator>
<dc:creator>Roosha K Parikh</dc:creator>
<dc:creator>Radoslaw Parma</dc:creator>
<dc:creator>Dhairya Patel</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>Bernard Prendergast</dc:creator>
<dc:creator>Nishath Quader</dc:creator>
<dc:creator>Michael J Reardon</dc:creator>
<dc:creator>Toby Rogers</dc:creator>
<dc:creator>Lucy M Safi</dc:creator>
<dc:creator>Stephanie L Sellers</dc:creator>
<dc:creator>Sabah Skaf</dc:creator>
<dc:creator>Giuseppe Tarantini</dc:creator>
<dc:creator>Didier Tchetche</dc:creator>
<dc:creator>Nicolas van Mieghem</dc:creator>
<dc:creator>Dee Dee Wang</dc:creator>
<dc:creator>John G Webb</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Steven J Yakubov</dc:creator>
<dc:creator>Victoria Delgado</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Hasan Jilaihawi</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Best Practices for Imaging of Transcatheter Valve Failure: An Update From the Heart Valve Collaboratory</dc:title>
<dc:identifier>pmid:40074470</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.017</dc:identifier>
</item>
<item>
<title>Lessons From Celect: Building Transparency and Trust in Medical Devices</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074469/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1038-1041. doi: 10.1016/j.jacc.2025.01.002.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074469/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074469</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.002>10.1016/j.jacc.2025.01.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074469</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Kushal T Kadakia</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lessons From Celect: Building Transparency and Trust in Medical Devices</dc:title>
<dc:identifier>pmid:40074469</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.002</dc:identifier>
</item>
<item>
<title>The Cardiovascular Epidemiology of Smoking: Past, Present, and Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074468/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1035-1037. doi: 10.1016/j.jacc.2025.01.017.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074468/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074468</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.017>10.1016/j.jacc.2025.01.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074468</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Oisin Galvin</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>John W McEvoy</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Cardiovascular Epidemiology of Smoking: Past, Present, and Future</dc:title>
<dc:identifier>pmid:40074468</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.017</dc:identifier>
</item>
<item>
<title>Association Between Cigarette Smoking and Subclinical Markers of Cardiovascular Harm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074467/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Smoking-relevant parameters show strong and dose-response relationships across 3 domains of subclinical markers of cardiovascular harm. The sensitivity of the tested subclinical markers to small increments in cigarette exposure suggests potential value in the regulation of new and existing tobacco products.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1018-1034. doi: 10.1016/j.jacc.2024.12.032.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cigarette smoking is a strong risk factor for cardiovascular harm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The study sought to explore the detailed relationships between smoking intensity, pack-years, and time since cessation with inflammation, thrombosis, and subclinical atherosclerosis markers of cardiovascular harm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We included 182,364 participants (mean age 58.2 years, 69.0% female) from 22 cohorts of the Cross Cohort Collaboration with self-reported smoking status, including smoking intensity and/or pack-years, and concurrent subclinical marker measurements. Markers were categorized into 3 domains: inflammation (high-sensitivity C-reactive protein, interleukin-6, glycoprotein acetylation), thrombosis (fibrinogen, D-dimer), and subclinical atherosclerosis (coronary artery calcium, carotid intima-media thickness, carotid plaque, and ankle-brachial index). Utilizing multivariate regression models and restricted cubic splines, we assessed associations of smoking status, intensity, pack-years, time since cessation, and subclinical markers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 15.3% of participants currently smoke (mean 16.7 cigarettes/day, mean 30.0 pack-years), and 34.6% of participants formerly smoked (median 19.0 years since quitting, mean 22.4 pack-years). Participants with a history of smoking showed higher levels of all subclinical markers compared with those who have never smoked, with stronger associations observed in those currently smoke. Among participants who currently smoke, smoking intensity showed a clear dose-response relationship with all markers, except for D-dimer, specifically with incremental 1% to 9% higher levels of subclinical markers per 10 cigarettes. After 20 cigarettes, the patterns appeared to plateau for blood markers, while they continued to increase for atherosclerosis markers. Among those who have ever smoked, robust dose-response relationships were observed for pack-years with all subclinical markers, with incremental 1% to 9% higher levels per 10 pack-years. The dose-response effects persisted after 20 pack-years for all markers, though with a milder slope. Among participants who smoked formerly, there were substantially lower levels of biomarkers with longer time since quitting, and most markers were not different compared with those who have never smoked by 30 years, except for the coronary artery calcium score, which remained 19% higher even beyond quitting after 30 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Smoking-relevant parameters show strong and dose-response relationships across 3 domains of subclinical markers of cardiovascular harm. The sensitivity of the tested subclinical markers to small increments in cigarette exposure suggests potential value in the regulation of new and existing tobacco products.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074467/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074467</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.032>10.1016/j.jacc.2024.12.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074467</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Zhiqi Yao</dc:creator>
<dc:creator>Erfan Tasdighi</dc:creator>
<dc:creator>Zeina A Dardari</dc:creator>
<dc:creator>Kunal K Jha</dc:creator>
<dc:creator>Ngozi Osuji</dc:creator>
<dc:creator>Tanuja Rajan</dc:creator>
<dc:creator>Ellen Boakye</dc:creator>
<dc:creator>Carlos J Rodriguez</dc:creator>
<dc:creator>Kunihiro Matsushita</dc:creator>
<dc:creator>Eleanor M Simonsick</dc:creator>
<dc:creator>Joao A C Lima</dc:creator>
<dc:creator>Rachel Widome</dc:creator>
<dc:creator>Debbie L Cohen</dc:creator>
<dc:creator>Lawrence J Appel</dc:creator>
<dc:creator>Amit Khera</dc:creator>
<dc:creator>Michael E Hall</dc:creator>
<dc:creator>Suzanne E Judd</dc:creator>
<dc:creator>Shelley A Cole</dc:creator>
<dc:creator>Ramachandran S Vasan</dc:creator>
<dc:creator>Emelia J Benjamin</dc:creator>
<dc:creator>Paulo A Lotufo</dc:creator>
<dc:creator>Isabela M Benseñor</dc:creator>
<dc:creator>Samar R El Khoudary</dc:creator>
<dc:creator>Emma Barinas-Mitchell</dc:creator>
<dc:creator>Imke Janssen</dc:creator>
<dc:creator>Bruce M Psaty</dc:creator>
<dc:creator>Charles B Eaton</dc:creator>
<dc:creator>Michael J LaMonte</dc:creator>
<dc:creator>Peggy M Cawthon</dc:creator>
<dc:creator>Eric S Orwoll</dc:creator>
<dc:creator>Marguerite R Irvin</dc:creator>
<dc:creator>Aruni Bhatnagar</dc:creator>
<dc:creator>Andrew P DeFilippis</dc:creator>
<dc:creator>Omar El-Shahaway</dc:creator>
<dc:creator>Michael J Blaha</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association Between Cigarette Smoking and Subclinical Markers of Cardiovascular Harm</dc:title>
<dc:identifier>pmid:40074467</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.032</dc:identifier>
</item>
<item>
<title>Transthyretin Amyloid Cardiomyopathy: Wherever Protein Stabilization Leads, Disease Stabilization Follows</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074466/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1015-1017. doi: 10.1016/j.jacc.2025.01.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074466/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074466</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.008>10.1016/j.jacc.2025.01.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074466</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Justin L Grodin</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transthyretin Amyloid Cardiomyopathy: Wherever Protein Stabilization Leads, Disease Stabilization Follows</dc:title>
<dc:identifier>pmid:40074466</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.008</dc:identifier>
</item>
<item>
<title>Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074465/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In participants with ATTR-CM, acoramidis reduced the composite of ACM or first CVH vs placebo, with an early effect driven by a reduction in CVH. (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy [ATTRibute-CM]; NCT03860935).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1003-1014. doi: 10.1016/j.jacc.2024.11.042.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed chronic disease associated with progressive heart failure that results in impaired quality of life, repeated hospitalizations, and premature death. Acoramidis is a selective, oral transthyretin stabilizer recently approved by the U.S. Food and Drug Administration for the treatment of ATTR-CM. In a phase 3, randomized, double-blind study (ATTRibute-CM [Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy]), acoramidis was well tolerated and showed clinical efficacy in improving the primary endpoint, a hierarchical combination of all-cause mortality (ACM), cardiovascular-related hospitalization (CVH), N-terminal pro-B-type natriuretic peptide level, and 6-minute walk distance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to characterize the efficacy of acoramidis on ACM and CVH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In ATTRibute-CM, participants with ATTR-CM were randomized 2:1 to receive acoramidis hydrochloride (800 mg twice daily) or placebo for 30 months. Efficacy analyses were conducted in the modified intention-to-treat population (participants with a baseline estimated glomerular filtration rate ≥30 mL/min/1.73 m<sup>2</sup>). CVH and the composite of ACM or first CVH were plotted by using Kaplan-Meier curves and summarized with a stratified Cox proportional hazards model. The annualized frequency of CVH was analyzed by using a negative binomial regression model. Subgroup analyses were conducted for the composite of ACM or first CVH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 632 participants randomized to treatment, 611 (97%) were included in efficacy analyses (acoramidis, n = 409; placebo, n = 202). Compared with placebo, acoramidis reduced the occurrence of the composite of ACM or first CVH (acoramidis, 35.9%; placebo, 50.5%; HR: 0.64; 95% CI: 0.50-0.83; P = 0.0008) and of first CVH (acoramidis, 26.7%; placebo, 42.6%; HR: 0.60; 95% CI: 0.45-0.80; P = 0.0005), with Kaplan-Meier curves separating at month 3 and continuing to diverge through month 30. Annualized frequency of CVH was reduced with acoramidis compared with placebo (acoramidis, 0.22; placebo, 0.45; relative risk ratio: 50%; 95% CI: 0.36-0.70; P &lt; 0.0001). The efficacy of acoramidis on the composite of ACM or first CVH was consistent across subgroups. Acoramidis was well tolerated, with no safety signals of potential clinical concern identified.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In participants with ATTR-CM, acoramidis reduced the composite of ACM or first CVH vs placebo, with an early effect driven by a reduction in CVH. (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy [ATTRibute-CM]; NCT03860935).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074465/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074465</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.042>10.1016/j.jacc.2024.11.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074465</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Daniel P Judge</dc:creator>
<dc:creator>Kevin M Alexander</dc:creator>
<dc:creator>Francesco Cappelli</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Simon D J Gibbs</dc:creator>
<dc:creator>Martha Grogan</dc:creator>
<dc:creator>Mazen Hanna</dc:creator>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Mathew S Maurer</dc:creator>
<dc:creator>Laura Obici</dc:creator>
<dc:creator>Prem Soman</dc:creator>
<dc:creator>Xiaofan Cao</dc:creator>
<dc:creator>Ted Lystig</dc:creator>
<dc:creator>Jean-François Tamby</dc:creator>
<dc:creator>Suresh Siddhanti</dc:creator>
<dc:creator>Adam Castaño</dc:creator>
<dc:creator>Leonid Katz</dc:creator>
<dc:creator>Jonathan C Fox</dc:creator>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy</dc:title>
<dc:identifier>pmid:40074465</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.042</dc:identifier>
</item>
<item>
<title>Genetic Testing for Cardiovascular Disease: Evidence Grows But Challenges Remain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40074464/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 18;85(10):1000-1002. doi: 10.1016/j.jacc.2025.01.007.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40074464/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40074464</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.007>10.1016/j.jacc.2025.01.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40074464</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>J Lukas Laws</dc:creator>
<dc:creator>Giovanni E Davogustto</dc:creator>
<dc:creator>Quinn S Wells</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Genetic Testing for Cardiovascular Disease: Evidence Grows But Challenges Remain</dc:title>
<dc:identifier>pmid:40074464</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.007</dc:identifier>
</item>
<item>
<title>Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40072462/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Among patients with obesity-related HFpEF, treatment with HU6 for 19 weeks led to modest but statistically significant weight loss without significant changes in peak VO2. Larger trials of longer duration are warranted to determine whether longer-term administration of HU6 can improve exercise function, quality of life, and cardiovascular outcomes in this increasingly common disorder.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 12. doi: 10.1001/jamacardio.2025.0103. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Excess body fat plays a pivotal role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF). HU6 is a novel, controlled metabolic accelerator that enhances mitochondrial uncoupling resulting in increased metabolism and fat-specific weight loss.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess efficacy and safety of HU6 in reducing body weight, improving peak volume of oxygen consumption (VO2) and body composition among patients with obesity-related HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The Exploratory Phase 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of HU6 for Subjects With Obese HFpEF (HuMAIN-HFpEF) trial was a multicenter, dose-escalation randomized clinical trial among patients with chronic stable HFpEF and obesity. Data were analyzed from July to October 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: HU6 treatment for 19 weeks, starting at 150 mg per day and potentially up titrated to 450 mg per day based on safety and tolerability vs placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was change in body weight.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 66 participants randomized (mean [SD] age, 64.5 [12] years; 38 female [58%]; mean [SD] weight, 110.9 [22.4] kg), 56 completed the trial. HU6 (vs placebo) significantly decreased weight (between-group difference, -2.86 kg; 95% CI, -4.68 to -1.04 kg; P = .003), total fat mass (between-group difference, -2.96 kg; 95% CI, -4.50 to -1.42 kg; P &lt; .001), and percentage visceral fat (between-group difference,-1.3%; 95% CI, -2.1 to -0.5%; P = .003), with no significant loss of muscle mass. There were no statistically significant changes in peak VO2, 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire score, high-sensitivity C-reactive protein level, N-terminal pro-brain natriuretic peptide level, or diastolic function. Serious adverse events were noted in 5 participants (4 in the HU6 group; 1 in the placebo group), including 1 death, all judged unrelated to treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among patients with obesity-related HFpEF, treatment with HU6 for 19 weeks led to modest but statistically significant weight loss without significant changes in peak VO2. Larger trials of longer duration are warranted to determine whether longer-term administration of HU6 can improve exercise function, quality of life, and cardiovascular outcomes in this increasingly common disorder.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05284617.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40072462/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40072462</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0103>10.1001/jamacardio.2025.0103</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40072462</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ambarish Pandey</dc:creator>
<dc:creator>Gregory D Lewis</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Andrew J Sauer</dc:creator>
<dc:creator>Sheldon Litwin</dc:creator>
<dc:creator>Kavita Sharma</dc:creator>
<dc:creator>Diane K Jorkasky</dc:creator>
<dc:creator>Elizabeth A Tarka</dc:creator>
<dc:creator>Shaharyar M Khan</dc:creator>
<dc:creator>Dalane W Kitzman</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:40072462</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0103</dc:identifier>
</item>
<item>
<title>FFR-Guided Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40072460/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this subgroup analysis of the FAME 3 randomized clinical trial, the relative benefit of CABG compared with FFR-guided PCI was similar among patients with and without diabetes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 12. doi: 10.1001/jamacardio.2025.0095. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Outcomes in patients with diabetes after fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) using current-generation drug-eluting stents (DES) compared with coronary artery bypass grafting (CABG) are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To investigate the relative treatment effect of PCI vs CABG according to diabetes status with respect to major adverse cardiac and cerebrovascular events (MACCE) at 3 years and to evaluate the impact of the SYNTAX score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This is a prespecified subgroup analysis of the FAME (Fractional Flow Reserve vs Angiography for Multivessel Evaluation) 3 trial, an investigator-initiated, randomized clinical trial conducted at 48 centers worldwide. The FAME 3 trial enrolled patients with 3-vessel coronary artery disease not involving the left main undergoing coronary revascularization between August 2014 and December 2019. Data analysis was conducted in August 2023. Clinical follow-up was performed at hospital discharge and at 1 month, 6 months, 1 year, 2 years, and 3 years after randomization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Either FFR-guided PCI with current-generation DES or CABG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was MACCE, defined as the composite of all-cause death, myocardial infarction, stroke, or repeat revascularization at 3 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1500 total patients enrolled, mean (SD) patient age was 65.1 (8.4) years, and 265 patients (17.7%) were female. The FAME 3 trial included 428 patients with diabetes (28.5%). Patients with diabetes, especially those receiving insulin, had a higher risk of MACCE at 3 years compared with those without diabetes. Regarding relative treatment effect, the risk of MACCE was higher after FFR-guided PCI compared with CABG in both patients with diabetes (hazard ratio [HR], 1.44; 95% CI, 0.91-2.28; P = .12) and those without diabetes (HR, 1.50; 95% CI, 1.08-2.07; P = .02), with no significant interaction (P for interaction = .94). In patients with a low SYNTAX score (&lt;23), there was no significant difference in MACCE between PCI and CABG, while in patients with an intermediate to high SYNTAX score (≥23), PCI had a higher risk of MACCE than CABG, regardless of diabetes status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this subgroup analysis of the FAME 3 randomized clinical trial, the relative benefit of CABG compared with FFR-guided PCI was similar among patients with and without diabetes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02100722.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40072460/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40072460</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0095>10.1001/jamacardio.2025.0095</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40072460</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Kuniaki Takahashi</dc:creator>
<dc:creator>Hisao Otsuki</dc:creator>
<dc:creator>Frederik M Zimmermann</dc:creator>
<dc:creator>Victoria Y Ding</dc:creator>
<dc:creator>Thomas Engstrøm</dc:creator>
<dc:creator>Hans Gustav Hørsted Thyregod</dc:creator>
<dc:creator>Branko Beleslin</dc:creator>
<dc:creator>Svetozar Putnik</dc:creator>
<dc:creator>Luke Tapp</dc:creator>
<dc:creator>Thomas Barker</dc:creator>
<dc:creator>Simon Redwood</dc:creator>
<dc:creator>Christopher Young</dc:creator>
<dc:creator>G Jan-Willem Bech</dc:creator>
<dc:creator>Gerard J F Hoohenkerk</dc:creator>
<dc:creator>Bernard De Bruyne</dc:creator>
<dc:creator>Nico H J Pijls</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>FAME 3 Trial Investigators</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>FFR-Guided Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Diabetes</dc:title>
<dc:identifier>pmid:40072460</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0095</dc:identifier>
</item>
<item>
<title>Food Insecurity and Incident Cardiovascular Disease Among Black and White US Individuals, 2000-2020</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40072427/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this prospective cohort study among participants in the CARDIA study, food insecurity was associated with incident CVD even after adjustment for socioeconomic factors, suggesting that food insecurity may be an important social deprivation measure in clinical assessment of CVD risk. Whether interventions to reduce food insecurity programs can potentially alleviate CVD should be further studied.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 12. doi: 10.1001/jamacardio.2025.0109. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Food insecurity is associated with prevalent cardiovascular disease (CVD), but studies have been limited to cross-sectional data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To study whether food insecurity is associated with incident CVD and to determine whether this association varies by sex, education, or race.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study was conducted among US adults without preexisting CVD participating in the CARDIA (Coronary Artery Risk Development in Young Adults) study from 2000 to August 31, 2020. Data analysis was conducted from December 2022 to April 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Food insecurity, defined as endorsing limitations in household food variety and/or food quantity, assessed in the period 2000-2001.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was CVD events, consisting of fatal and nonfatal coronary heart disease, heart failure, stroke, transient ischemic attack, or peripheral arterial disease, identified annually through August 31, 2020.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 3616 total participating adults, mean (SD) age was 40.1 (3.6) years, and 2027 participants (56%) were female. Of 3616 participants, 1696 (47%) self-reported Black race and 529 participants (15%) had food insecurity at baseline. Individuals with food insecurity were more likely to self-identify as Black and report lower educational attainment. The mean (SD) follow-up period was 18.8 (3.4) years, during which 255 CVD events occurred: 57 events (11%) in food-insecure participants and 198 events (6%) in food-secure participants over the study period. After adjusting for age, sex, and field center, food insecurity was associated with incident CVD (adjusted hazard ratio [aHR], 1.90; 95% CI, 1.41-2.56). The association persisted (aHR, 1.47; 95% CI, 1.08-2.01) after further adjustment for the socioeconomic factors of education, marital status, and usual source of medical care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this prospective cohort study among participants in the CARDIA study, food insecurity was associated with incident CVD even after adjustment for socioeconomic factors, suggesting that food insecurity may be an important social deprivation measure in clinical assessment of CVD risk. Whether interventions to reduce food insecurity programs can potentially alleviate CVD should be further studied.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40072427/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40072427</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0109>10.1001/jamacardio.2025.0109</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40072427</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Jenny Jia</dc:creator>
<dc:creator>Mercedes R Carnethon</dc:creator>
<dc:creator>Mandy Wong</dc:creator>
<dc:creator>Cora E Lewis</dc:creator>
<dc:creator>Pamela J Schreiner</dc:creator>
<dc:creator>Namratha R Kandula</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Food Insecurity and Incident Cardiovascular Disease Among Black and White US Individuals, 2000-2020</dc:title>
<dc:identifier>pmid:40072427</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0109</dc:identifier>
</item>
<item>
<title>Exercise-Induced Dyspnea in an Older Woman With a History of Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40072426/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 12. doi: 10.1001/jamacardio.2025.0115. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40072426/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40072426</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0115>10.1001/jamacardio.2025.0115</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40072426</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Soundous M'Rabet</dc:creator>
<dc:creator>Jean-Christophe Eicher</dc:creator>
<dc:creator>Charles Guenancia</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Exercise-Induced Dyspnea in an Older Woman With a History of Coronary Artery Disease</dc:title>
<dc:identifier>pmid:40072426</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0115</dc:identifier>
</item>
<item>
<title>PCSK9 Promotes LDLR Degradation by Preventing SNX17-Mediated LDLR Recycling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40071387/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: PCSK9 promotes LDLR degradation by preventing SNX17-mediated LDLR recycling. Patients with sequence variations in FH leading to defects in LDLR recycling are resistant to PCSK9 inhibitors. Genetic diagnosis and alternative drugs independent of LDLR will be needed for treatment of these patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 12. doi: 10.1161/CIRCULATIONAHA.124.072336. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Low-density lipoprotein (LDL) is internalized into cells mainly through LDLR (LDL receptor)-mediated endocytosis. In an acidic endosome, LDLR is released from LDL and recycles back to the cell surface, whereas LDL is left in the endosome and degraded in the lysosome. Circulating PCSK9 (proprotein convertase subtilisin/kexin 9) binds with LDLR and is internalized into the endosome, similar to LDL. In an acidic endosome, LDLR fails to disassociate from PCSK9, and both proteins are degraded in the lysosome. PCSK9 inhibitors are widely used for treating hypercholesterolemia. However, how PCSK9 diverts LDLR to the lysosome for degradation remains elusive. Some patients are resistant to PCSK9 inhibitors, for unknown reasons.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Both in vitro and in vivo approaches were used to investigate the molecular and cellular mechanisms of PCSK9-mediated LDLR degradation. LDLR containing <i>FH</i> sequence variations was expressed in <i>LDLR</i> knockout mice and knockout HuH7 cells to evaluate their response to PCSK9 and PCSK9 inhibitors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Acidic pH induces a conformational change in LDLR extracellular domain and promotes its interaction with SNX17 (sorting nexin 17) through the intracellular domain. Knocking down <i>SNX17</i> abolishes LDLR recycling and causes accelerated degradation in the lysosome. PCSK9 prevents the acidic pH-induced conformational change in LDLR and blocks its interaction with SNX17. Knocking down <i>SNX17</i> abolishes PCSK9-mediated LDLR degradation. Any <i>FH</i> sequence variations that disrupt LDLR recycling are unresponsive to PCSK9 or PCSK9 inhibitors, even though they can internalize LDL.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: PCSK9 promotes LDLR degradation by preventing SNX17-mediated LDLR recycling. Patients with sequence variations in <i>FH</i> leading to defects in LDLR recycling are resistant to PCSK9 inhibitors. Genetic diagnosis and alternative drugs independent of LDLR will be needed for treatment of these patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40071387/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40071387</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072336>10.1161/CIRCULATIONAHA.124.072336</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40071387</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>YangYang Guan</dc:creator>
<dc:creator>Xiaomin Liu</dc:creator>
<dc:creator>Zetian Yang</dc:creator>
<dc:creator>Xinyu Zhu</dc:creator>
<dc:creator>Min Liu</dc:creator>
<dc:creator>Mingkun Du</dc:creator>
<dc:creator>Xiaowei Pan</dc:creator>
<dc:creator>Yan Wang</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>PCSK9 Promotes LDLR Degradation by Preventing SNX17-Mediated LDLR Recycling</dc:title>
<dc:identifier>pmid:40071387</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072336</dc:identifier>
</item>
<item>
<title>Myeloid Fatty Acid Metabolism Activates Neighboring Hematopoietic Stem Cells to Promote Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40071347/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250313041557&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings identify a significant new stem cell signature of cardiometabolic HFpEF and support a role for myeloid maladaptive fatty acid metabolism in the promotion of systemic inflammation and cardiac diastolic dysfunction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 12. doi: 10.1161/CIRCULATIONAHA.124.070248. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment options remain limited. The HFpEF syndrome is associated with a high comorbidity burden, including high prevalence of obesity and hypertension. Although inflammation is implicated to play a key role in HFpEF pathophysiology, underlying causal mechanisms remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Comparing patient samples and animal models, we defined the innate immune response during HFpEF in situ and through flow cytometry and single-cell RNA sequencing. After identifying transcriptional and cell signatures, we implemented a high-fat diet and hypertensive model of HFpEF and tested roles for myeloid and hematopoietic stem cells during HFpEF. Contributions of macrophage metabolism were also evaluated, including through mass spectrometry and carbon labeling. Primary macrophages were studied ex vivo to gain insight into complementary cell-intrinsic mechanisms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Here we report evidence that patients with cardiometabolic HFpEF exhibit elevated peripheral blood hematopoietic stem cells. This phenotype was conserved across species in a murine mode of high-fat diet and hypertension. Hematopoietic stem cell proliferation was coupled to striking remodeling of the peripheral hematopoietic stem cell niche and expression of the macrophage adhesion molecule <i>Vcam1</i>. This could be partially inhibited by sodium-glucose cotransporter-2 inhibitors and explained by elevated fatty acid metabolism in macrophage mitochondria, which in turn remodeled the <i>Vcam1</i> promoter to enhance its expression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings identify a significant new stem cell signature of cardiometabolic HFpEF and support a role for myeloid maladaptive fatty acid metabolism in the promotion of systemic inflammation and cardiac diastolic dysfunction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40071347/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250313041557&v=2.18.0.post9+e462414">40071347</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070248>10.1161/CIRCULATIONAHA.124.070248</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40071347</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mallory Filipp</dc:creator>
<dc:creator>Zhi-Dong Ge</dc:creator>
<dc:creator>Matthew DeBerge</dc:creator>
<dc:creator>Connor Lantz</dc:creator>
<dc:creator>Kristofor Glinton</dc:creator>
<dc:creator>Peng Gao</dc:creator>
<dc:creator>Sasha Smolgovsky</dc:creator>
<dc:creator>Jingbo Dai</dc:creator>
<dc:creator>You-Yang Zhao</dc:creator>
<dc:creator>Laurent Yvan-Charvet</dc:creator>
<dc:creator>Pilar Alcaide</dc:creator>
<dc:creator>Samuel E Weinberg</dc:creator>
<dc:creator>Gabriele G Schiattarella</dc:creator>
<dc:creator>Joseph A Hill</dc:creator>
<dc:creator>Matthew J Feinstein</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Edward B Thorp</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Myeloid Fatty Acid Metabolism Activates Neighboring Hematopoietic Stem Cells to Promote Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:40071347</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070248</dc:identifier>
</item>





























</channel>
</rss>